China-Administration of Nicorandil Group(CHANGE)

PHASE4CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

February 24, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

October 1, 2021

Conditions
Myocardial InfarctionPercutaneous Coronary InterventionNicorandil
Interventions
DRUG

Nicorandil

After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h

OTHER

Placebo

After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h

Trial Locations (1)

Unknown

CHINA, Beijing

All Listed Sponsors
collaborator

First People's Hospital of Yulin

OTHER

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Wuhan Asia Heart Hospital

OTHER

collaborator

Hainan Hospital of PLA General Hospital

UNKNOWN

collaborator

Zunyi Medical College

OTHER

collaborator

Guizhou Provincial People's Hospital

OTHER

collaborator

Second Affiliated Hospital of Nanchang University

OTHER

collaborator

The Second Hospital of Hebei Medical University

OTHER

lead

Chinese PLA General Hospital

OTHER

NCT03445728 - China-Administration of Nicorandil Group(CHANGE) | Biotech Hunter | Biotech Hunter